Failure of GPI compounds to display neurotrophic activity in vitro and in vivo
Authors:
- Geneviève LorentGLGeneviève Lorent
- Bruno FuksBFBruno Fuks
- Renée GriméeRGRenée Grimée
- Patrice TalagaPTPatrice Talaga
- Jean DaliersJDJean Daliers
- Henrik KlitgaardHKHenrik Klitgaard
- 1 March 2001
- journal article
- Published by Elsevier in European Journal of Pharmacology
- Vol. 415 (2-3) , 173-180
Abstract
No abstract availableKeywords
This publication has 27 references indexed in Scilit:
- Immunophilins: Beyond ImmunosuppressionJournal of Medicinal Chemistry, 1998
- Immunophilin ligands for the treatment of neurological disordersExpert Opinion on Therapeutic Patents, 1998
- A Novel Immunophilin Ligand: Distinct Branching Effects on Dopaminergic Neurons in Culture and Neurotrophic Actions after Oral Administration in an Animal Model of Parkinson's DiseaseNeurobiology of Disease, 1998
- A Nonimmunosuppressant FKBP-12 Ligand Increases Nerve RegenerationExperimental Neurology, 1997
- Animal models of Parkinson's disease: An empirical comparison with the phenomenology of the disease in manJournal of Neural Transmission, 1996
- Intracellular Signaling Pathways Activated by Neuropathic FactorsAnnual Review of Neuroscience, 1996
- Neurotrophic Factors in Central Nervous System TraumaJournal of Neurotrauma, 1995
- Chemistry and Biology of the Immunophilins and Their Immunosuppressive LigandsScience, 1991
- A cytosolic binding protein for the immunosuppressant FK506 has peptidyl-prolyl isomerase activity but is distinct from cyclophilinNature, 1989
- Cyclophilin and peptidyl-prolyl cis-trans isomerase are probably identical proteinsNature, 1989